Literature DB >> 31097866

Optimal inference for Simon's two-stage design with over or under enrollment at the second stage.

Guogen Shan1, John J Chen2.   

Abstract

Simon's two-stage designs are widely used in clinical trials to assess the activity of a new treatment. In practice, it is often the case that the second stage sample size is different from the planned one. For this reason, the critical value for the second stage is no longer valid for statistical inference. Existing approaches for making statistical inference are either based on asymptotic methods or not optimal. We propose an approach to maximize the power of the study while maintaining the type I error rate where the type I error rate and power are calculated exactly from binomial distributions. The critical values of the proposed approach are numerically searched by an intelligent algorithm over the complete parameter space. It is guaranteed that the proposed approach is at least as powerful as the conditional power approach which is a valid but non-optimal approach. The power gain of the proposed approach can be substantial as compared to the conditional power approach. We apply the proposed approach to a real Phase II clinical trial.

Entities:  

Keywords:  Adaptive design; Clinical trials; Conditional power; Sample size; Simon’s two-stage design

Year:  2017        PMID: 31097866      PMCID: PMC6516485          DOI: 10.1080/03610918.2017.1307398

Source DB:  PubMed          Journal:  Commun Stat Simul Comput        ISSN: 0361-0918            Impact factor:   1.118


  18 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Unconditional tests for comparing two ordered multinomials.

Authors:  Guogen Shan; Changxing Ma
Journal:  Stat Methods Med Res       Date:  2012-06-13       Impact factor: 3.021

3.  Planned versus attained design in phase II clinical trials.

Authors:  S J Green; S Dahlberg
Journal:  Stat Med       Date:  1992-05       Impact factor: 2.373

4.  Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.

Authors:  Guogen Shan; Changxing Ma; Alan D Hutson; Gregory E Wilding
Journal:  J Biopharm Stat       Date:  2013       Impact factor: 1.051

5.  Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design.

Authors:  Yujun Wu; Weichung J Shih
Journal:  Stat Med       Date:  2008-12-20       Impact factor: 2.373

6.  Sample size calculation based on efficient unconditional tests for clinical trials with historical controls.

Authors:  Guogen Shan; Sheniz Moonie; Jay Shen
Journal:  J Biopharm Stat       Date:  2014-12-31       Impact factor: 1.051

7.  Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.

Authors:  Ariela Noy; David T Scadden; Jeannette Lee; Bruce J Dezube; David Aboulafia; Anil Tulpule; Sharon Walmsley; Parkash Gill
Journal:  J Clin Oncol       Date:  2004-12-14       Impact factor: 44.544

8.  A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.

Authors:  Yimei Li; Rosemarie Mick; Daniel F Heitjan
Journal:  Clin Trials       Date:  2012-04-20       Impact factor: 2.486

9.  Proper inference from Simon's two-stage designs.

Authors:  Tatsuki Koyama; Heidi Chen
Journal:  Stat Med       Date:  2008-07-20       Impact factor: 2.373

10.  Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.

Authors:  Henry B Koon; Susan E Krown; Jeannette Y Lee; Kord Honda; Suthee Rapisuwon; Zhenghe Wang; David Aboulafia; Erin G Reid; Michelle A Rudek; Bruce J Dezube; Ariela Noy
Journal:  J Clin Oncol       Date:  2013-12-30       Impact factor: 44.544

View more
  2 in total

1.  Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients.

Authors:  Lingyun Ji; Jennifer Whangbo; John E Levine; Todd A Alonzo
Journal:  Contemp Clin Trials       Date:  2022-07-19       Impact factor: 2.261

2.  Correlation Coefficients for a Study with Repeated Measures.

Authors:  Guogen Shan; Hua Zhang; Tao Jiang
Journal:  Comput Math Methods Med       Date:  2020-03-26       Impact factor: 2.238

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.